Cargando…
Precision medicine in neurodegeneration: the IHI-PROMINENT project
Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatm...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433183/ https://www.ncbi.nlm.nih.gov/pubmed/37602259 http://dx.doi.org/10.3389/fneur.2023.1175922 |
_version_ | 1785091593015918592 |
---|---|
author | Tate, Ashley Suárez-Calvet, Marc Ekelund, Mats Eriksson, Sven Eriksdotter, Maria Van Der Flier, Wiesje M. Georges, Jean Kivipelto, Miia Kramberger, Milica G. Lindgren, Peter López, Juan Domingo Gispert Lötjönen, Jyrki Persson, Sofie Pla, Sandra Solomon, Alina Thurfjell, Lennart Wimo, Anders Winblad, Bengt Jönsson, Linus |
author_facet | Tate, Ashley Suárez-Calvet, Marc Ekelund, Mats Eriksson, Sven Eriksdotter, Maria Van Der Flier, Wiesje M. Georges, Jean Kivipelto, Miia Kramberger, Milica G. Lindgren, Peter López, Juan Domingo Gispert Lötjönen, Jyrki Persson, Sofie Pla, Sandra Solomon, Alina Thurfjell, Lennart Wimo, Anders Winblad, Bengt Jönsson, Linus |
author_sort | Tate, Ashley |
collection | PubMed |
description | Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes. |
format | Online Article Text |
id | pubmed-10433183 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-104331832023-08-18 Precision medicine in neurodegeneration: the IHI-PROMINENT project Tate, Ashley Suárez-Calvet, Marc Ekelund, Mats Eriksson, Sven Eriksdotter, Maria Van Der Flier, Wiesje M. Georges, Jean Kivipelto, Miia Kramberger, Milica G. Lindgren, Peter López, Juan Domingo Gispert Lötjönen, Jyrki Persson, Sofie Pla, Sandra Solomon, Alina Thurfjell, Lennart Wimo, Anders Winblad, Bengt Jönsson, Linus Front Neurol Neurology Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Recent advances in diagnostics and approval for new pharmaceutical treatments for Alzheimer’s disease (AD), the most common etiology of dementia, heralds the beginning of precision medicine in this field. However, their implementation will challenge an already over-burdened healthcare systems. There is a need for innovative digital solutions that can drive the related clinical pathways and optimize and personalize care delivery. Public-private partnerships are ideal vehicles to tackle these challenges. Here we describe the Innovative Health Initiative (IHI) public-private partnership project PROMINENT that has been initiated by connecting leading dementia researchers, medical professionals, dementia patients and their care partners with the latest innovative health technologies using a precision medicine based digital platform. The project builds upon the knowledge and already implemented digital tools from several collaborative initiatives that address new models for early detection, diagnosis, and monitoring of AD and other neurodegenerative disorders. The project aims to provide support to improvement efforts to each aspect of the care pathway including diagnosis, prognosis, treatment, and data collection for real world evidence and cost effectiveness studies. Ultimately the PROMINENT project is expected to lead to cost-effective care and improved health outcomes. Frontiers Media S.A. 2023-08-02 /pmc/articles/PMC10433183/ /pubmed/37602259 http://dx.doi.org/10.3389/fneur.2023.1175922 Text en Copyright © 2023 Tate, Suárez-Calvet, Ekelund, Eriksson, Eriksdotter, Van Der Flier, Georges, Kivipelto, Kramberger, Lindgren, López, Lötjönen, Persson, Pla, Solomon, Thurfjell, Wimo, Winblad and Jönsson. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Neurology Tate, Ashley Suárez-Calvet, Marc Ekelund, Mats Eriksson, Sven Eriksdotter, Maria Van Der Flier, Wiesje M. Georges, Jean Kivipelto, Miia Kramberger, Milica G. Lindgren, Peter López, Juan Domingo Gispert Lötjönen, Jyrki Persson, Sofie Pla, Sandra Solomon, Alina Thurfjell, Lennart Wimo, Anders Winblad, Bengt Jönsson, Linus Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title | Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title_full | Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title_fullStr | Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title_full_unstemmed | Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title_short | Precision medicine in neurodegeneration: the IHI-PROMINENT project |
title_sort | precision medicine in neurodegeneration: the ihi-prominent project |
topic | Neurology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10433183/ https://www.ncbi.nlm.nih.gov/pubmed/37602259 http://dx.doi.org/10.3389/fneur.2023.1175922 |
work_keys_str_mv | AT tateashley precisionmedicineinneurodegenerationtheihiprominentproject AT suarezcalvetmarc precisionmedicineinneurodegenerationtheihiprominentproject AT ekelundmats precisionmedicineinneurodegenerationtheihiprominentproject AT erikssonsven precisionmedicineinneurodegenerationtheihiprominentproject AT eriksdottermaria precisionmedicineinneurodegenerationtheihiprominentproject AT vanderflierwiesjem precisionmedicineinneurodegenerationtheihiprominentproject AT georgesjean precisionmedicineinneurodegenerationtheihiprominentproject AT kivipeltomiia precisionmedicineinneurodegenerationtheihiprominentproject AT krambergermilicag precisionmedicineinneurodegenerationtheihiprominentproject AT lindgrenpeter precisionmedicineinneurodegenerationtheihiprominentproject AT lopezjuandomingogispert precisionmedicineinneurodegenerationtheihiprominentproject AT lotjonenjyrki precisionmedicineinneurodegenerationtheihiprominentproject AT perssonsofie precisionmedicineinneurodegenerationtheihiprominentproject AT plasandra precisionmedicineinneurodegenerationtheihiprominentproject AT solomonalina precisionmedicineinneurodegenerationtheihiprominentproject AT thurfjelllennart precisionmedicineinneurodegenerationtheihiprominentproject AT wimoanders precisionmedicineinneurodegenerationtheihiprominentproject AT winbladbengt precisionmedicineinneurodegenerationtheihiprominentproject AT jonssonlinus precisionmedicineinneurodegenerationtheihiprominentproject AT precisionmedicineinneurodegenerationtheihiprominentproject |